Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2.5 ± 0.8 years. Prednisone was withdrawn in all but two patients. Anti-acetylcholine antibodies and MG score for disease severity decreased significantly and muscular strength increased by 39%. Complete stable remission was achieved in 5% of patients and pharmacologic remission in 87.3%. All patients resumed full activities of daily living.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Reply to Sanders et al
- José M. Ponseti, Myasthenia Gravis Unit, Department of Surgery, Hospital General Universitari, Passeig Vall d'Hebron 119-129, E-08035 Barcelona, Spainjmponseti@vhebron.net
- J. Azem, J.M. Fort, M. López-Cano, R. Vilallonga, M. Buera, C. Cervera, M. Armengol
Submitted September 15, 2005 - Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis
- Donald B. Sanders, Duke University Medical Center, Box 3403 DUMC Durham, NC 27710Donald.Sanders@Duke.edu
- The Clinical Research Standards Committee of the Medical/Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Johan A. Aarli, Gary R. Cutter, Alfred Jaretzki III, Henry J. Kaminski, Lawrence H. Phillips II, Donald B. Sanders
Submitted September 15, 2005
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Article
Rituximab as treatment for anti-MuSK myasthenia gravisMulticenter blinded prospective reviewMichael K. Hehir, Lisa D. Hobson-Webb, Michael Benatar et al.Neurology, August 11, 2017 -
Brief Communications
Mycophenolate mofetil for myasthenia gravisAn analysis of efficacy, safety, and tolerabilityM.N. Meriggioli, E. Ciafaloni, K.A. Al-Hayk et al.Neurology, November 24, 2003 -
Article
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B. Aban et al.Neurology, July 01, 2020 -
Articles
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravisD. B. Sanders, I. K. Hart, R. Mantegazza et al.Neurology, April 23, 2008